ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

被引:7
|
作者
Nguyen, Vuong [1 ]
Leung, King Fai Calvin [1 ]
Nguyen, Chu Luan [1 ]
Squirrell, David [2 ]
Essex, Rohan [3 ]
Arnold, Jennifer [4 ]
Young, Stephanie [5 ]
Barthelmes, Daniel [1 ,6 ]
Gillies, Mark [1 ]
机构
[1] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia
[2] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand
[3] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia
[4] Marsden Eye Specialists, Parramatta, NSW, Australia
[5] Gladesville Retina, Gladesville, NSW, Australia
[6] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland
基金
英国医学研究理事会;
关键词
observational data; registry; data quality; audit; DATA QUALITY; INTRAVITREAL THERAPY; 12-MONTH OUTCOMES; RELIABILITY; GUIDELINES; EPITHELIUM; CATARACT; PROGRAM; AUDIT;
D O I
10.1097/IAE.0000000000002485
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the accuracy of an observational database that tracks real-world treatment outcomes for neovascular age-related macular degeneration. Methods: We audited 245 randomly sampled eyes from 189 patients with 3,356 visits from 11 doctors in the Fight Retinal Blindness! database. Sex, birth year, previous treatments received, treatment, and visual acuity were validated against the clinical notes. Error rates, the proportion of missed visits (the number of visits present in the patient record but not entered into Fight Retinal Blindness!), the level of agreement using Cohen's kappa (kappa) and intraclass correlation coefficients, and positive and negative predictive values were calculated. A visual acuity error was defined as an absolute difference of >= 5 letters. Results: The overall error rate was 3.5% (95% confidence interval: 3.1-3.9). The error rate for visual acuity was 5.1% (95% confidence interval: 4.2-5.9) and <5% for the remaining fields. The level of agreement for each field ranged from good to excellent (kappa or intraclass correlation >= 0.75). The positive predictive value and negative predictive value for visits were 99% and 89%, respectively. The proportion of missed visits was 10.2%. Conclusion: Accuracy of the Fight Retinal Blindness! database was good (>95%). The rate of missed visits was high, possibly due to the high burden of retrospective data entry or patients switching practitioners during treatment.
引用
收藏
页码:866 / 872
页数:7
相关论文
共 50 条
  • [1] Neovascular Age-Related Macular Degeneration
    Veritti, Daniele
    Sarao, Valentina
    Lanzetta, Paolo
    OPHTHALMOLOGICA, 2012, 227 : 11 - 20
  • [2] Macular translocation for neovascular age-related macular degeneration
    Eandi, Chiara M.
    Giansanti, Fabrizio
    Virgili, Gianni
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [3] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [4] Pegaptanib for neovascular age-related macular degeneration
    Gragoudas, ES
    Adamis, AP
    Cunningham, ET
    Feinsod, M
    Guyer, DR
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27): : 2805 - 2816
  • [5] Management of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Pruente, Christian
    PROGRESS IN RETINAL AND EYE RESEARCH, 2007, 26 (04) : 437 - 451
  • [6] Imaging in Neovascular Age-Related Macular Degeneration
    Gess, Adam J.
    Fung, Anne E.
    Rodriguez, Jorge G.
    SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 225 - 233
  • [7] Aflibercept for neovascular age-related macular degeneration
    Sarwar, Salman
    Clearfield, Elizabeth
    Soliman, Mohamed Kamel
    Sadiq, Mohammad Ali
    Baldwin, Andrew J.
    Hanout, Mostafa
    Agarwal, Aniruddha
    Sepah, Yasir J.
    Do, Diana V.
    Quan Dong Nguyen
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [8] Radiotherapy for neovascular age-related macular degeneration
    Evans, Jennifer R.
    Sivagnanavel, Vasuki
    Chong, Victor
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [9] Bevacizumab for Neovascular Age-Related Macular Degeneration
    Silva, Aline
    Furlan, Luiz
    Elias, Flavia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 75 - 76
  • [10] Ranibizumab for neovascular age-related macular degeneration
    Gillies, Mark C.
    Wong, Tien Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 748 - 749